Clinical Trial: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Pancreatic Cancer
Study Type: INTERVENTIONAL
Official Title: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Brief Summary:
The purpose of this study is to evaluate the safety and clinical activity of tadalafil, pembrolizumab, ipilimumab, and CRS-207 in subjects with metastatic pancreatic adenocarcinoma who have progressed after at least 1 prior chemotherapy regimen.
Read more